Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;49(3):607-614.
doi: 10.1016/j.burns.2022.11.007. Epub 2022 Dec 5.

Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers

Joshua S Carson  1 , Jeffrey E Carter  2 , William L Hickerson  3 , Lisa Rae  4 , Syed F Saquib  5 , Lucy A Wibbenmeyer  6 , Russell V Becker  7 , Jeremiah A Sparks  8 , Thomas P Walsh  9
Affiliations
Free article

Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers

Joshua S Carson et al. Burns. 2023 May.
Free article

Abstract

Background: Autologous skin cell suspension (ASCS) is a treatment for acute thermal burn injuries associated with significantly lower donor skin requirements than conventional split-thickness skin grafts (STSG). Projections using the BEACON model suggest that among patients with small burns (total body surface area [TBSA]<20 %), use of ASCS± STSG leads to a shorter length of stay (LOS) in hospital and cost savings compared with use of STSG alone. This study evaluated whether data from real-world clinical practice corroborate these findings.

Materials and methods: Electronic medical record data were collected from January 2019 through August 2020 from 500 healthcare facilities in the United States. Adult patients receiving inpatient treatment with ASCS± STSG for small burns were identified and matched to patients receiving STSG using baseline characteristics. LOS was assumed to cost $7554/day and to account for 70 % of overall costs. Mean LOS and costs were calculated for the ASCS± STSG and STSG cohorts.

Results: A total of 151 ASCS± STSG and 2243 STSG cases were identified; 63.0 % of patients were male and the average age was 44.2 years. Sixty-three matches were made between cohorts. LOS was 18.5 days with ASCS± STSG and 20.6 days with STSG (difference: 2.1 days [10.2 %]). This difference led to bed cost savings of $15,587.62 per ASCS± STSG patient. Overall cost savings with ASCS± STSG were $22,268.03 per patient.

Conclusions: Analysis of real-world data shows that treatment of small burn injuries with ASCS± STSG provides reduced LOS and substantial cost savings compared with STSG, supporting the validity of the BEACON model projections.

Keywords: Autologous skin cell suspension; Cost savings; Length of stay; Real-world data; Small burn injury.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest J.S. Carson is a consultant to AVITA Medical, Valencia, CA, USA. Mallinckrodt Pharmaceutical, and the United States Department of Defense (via General Dynamics). J.E. Carter is a consultant to SpectralMD Inc. and AVITA Medical, Valencia, CA, USA; he is a stockholder of PermeaDerm Inc. & SpectralMD Inc. and has research supported by Spirit of Charity Foundation Burn Research Fund. W.L. Hickerson is a consultant to AVITA Medical, Valencia, CA, USA, Vericel, and Avadim Health Inc., and is a stockholder of PermeaDerm. L. Rae and S. Saquib have no conflicts to disclose. L. Wibbenmeyer and R. Becker are consultants to AVITA Medical, Valencia, CA, USA. J. Sparks and T. Walsh are employees of AVITA Medical, Valencia, CA, USA.

LinkOut - more resources